Creating an impact on treatment success
Base your diagnosis on a fully validated and integrated value chain. Discover our comprehensive portfolio of solutions — from staining to assays to digital pathology.
Base your diagnosis on a fully validated and integrated value chain. Discover our comprehensive portfolio of solutions — from staining to assays to digital pathology.
Our comprehensive portfolio offers multiple tests that help determine the right treatment for each patient. HER2 testing for instance, can be used to inform treatment decisions – and this has already supported a 37% relative improvement in the overall survival rate of women with HER2-positive breast cancer.1
Our integrated pathology instruments, clinically significant assays, and digital tools help increase diagnostic certainty and optimize medical value for every patient.
The only automated H&E system with individual slide-staining technology. Designed to improve your workflow, the staining quality, and safety for both patients and technicians.
This fully automated instrument offers 30 independent slide drawers and a single-piece workflow – supporting a large menu of 250+ ready-to-use assays.
Our extensive portfolio consists of robust and highly sensitive assays for breast cancer diagnostics – ready-to-use and of high medical value.2-5
ER (SP1) antibody has shown the most consistent performance and superior quality when compared to other ER-clones.6
The PR (1E2) antibody provides significant value as a prognostic factor and response prediction of hormone therapy, even in ER-negative patients.
Staining for Ki-67 can be used to aid in assessing the proliferative activity of normal and neoplastic tissue and can help deliver a confident assessment of tumor aggressiveness.
CE IVD marked assay, indicated as an aid in the assessment of patients with breast or stomach cancer, for whom Herceptin treatment is considered.
The new VENTANA HER2 Dual ISH DNA Probe Cocktail assay helps identify breast and gastric cancer patients eligible for treatment with HER2-targeted personalized therapies.
The SP142 assay is the approved diagnostic test used to identify mTNBC patients most likely to benefit from the addition of atezolizumab to Nab-Paclitaxel.
Our digital solutions enable precision diagnosis in support of better, more personalized healthcare.
Our solution enables you to:
uPath can help you streamline communication and efficiency in the lab: this efficient and sustainable digital pathology solution provides users quick and easy access to the information they need.
Intelligent and insightful digital pathology image analysis algorithms that empower pathologists to confidently, accurately, and objectively assess whole tissue slide images.
Would you like to know more about our integrated solutions, or do you have other questions? Leave your details and we will get in touch with you.
Matthias Bodmer
Disease Area Manager Oncology